Logistics of Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Seminars in Nuclear Medicine

Volumn 34, Issue 1 SUPPL.1, 2004, Pages 14-19

  Zimmer, A Michael ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131;

ANTIBODY DETECTION; B CELL LYMPHOMA; CANCER GRADING; CELL TRANSFORMATION; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; DRUG INDICATION; HUMAN; IMAGE ANALYSIS; NONHODGKIN LYMPHOMA; NUCLEAR MEDICINE; ONCOLOGY; RADIATION DOSE DISTRIBUTION; RADIOIMMUNOTHERAPY; RELAPSE; REVIEW; STATISTICAL MODEL;

EID: 0842303401     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2003.11.001     Document Type: Article

References (11)

1. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 43:267-272, 2002
2. Zevalin (ibritumomab tiuxetan) prescribing information. San Diego, CA, IDEC Pharmaceuticals Corporation, 2002
3. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 2:457-470, 1996
4. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777, 2000
5. Wiseman GA, White CA, Sparks RB, et al: Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 39:181-194, 2001
6. Wiseman GA, Leigh B, Erwin WD, et al: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94(suppl 4): 1349-1357, 2002
7. Colcher D: Centralized radiolabeling of antibodies for radioimmunotherapy. J Nucl Med 39:11S-13S, 1998 (suppl 8)
8. 90Y ibritumomab tiuxetan activity. J Nucl Med 44:317P, 2003 (suppl 1137)
9. Wiseman G, Leigh B, Witzig T, et al: Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 28:1198, 2001 (abstr)
10. Zimmer AM, Carey AM, Spies SM: Effectiveness of specific vial and syringe shields in reducing radiation exposure from Y-90 Zevalin. J Nucl Med 43:45P, 2002
11. Zanzonico PB, Binkert BL, Goldsmith SJ: Bremsstrahlung radiation exposure from pure beta-ray emitters. J Nucl Med 40:1024-1028, 1999